Compare COLM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLM | ADPT |
|---|---|---|
| Founded | 1938 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 1997 | 2019 |
| Metric | COLM | ADPT |
|---|---|---|
| Price | $66.46 | $17.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $62.50 | $17.78 |
| AVG Volume (30 Days) | 425.0K | ★ 3.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $3,042,478,000.00 | $276,976,000.00 |
| Revenue This Year | $3.73 | $3.98 |
| Revenue Next Year | $3.29 | $22.72 |
| P/E Ratio | $101.46 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $47.48 | $9.96 |
| 52 Week High | $69.06 | $20.76 |
| Indicator | COLM | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 59.38 |
| Support Level | $53.13 | $14.87 |
| Resistance Level | $68.10 | $17.72 |
| Average True Range (ATR) | 1.95 | 1.37 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 52.49 | 58.31 |
Columbia Sportswear Co makes outdoor and active-lifestyle apparel, footwear, equipment, and accessories that it sells under four primary brands: Columbia, Sorel, Mountain Hardwear, and prAna. The majority of sales are in the United States, but the company also has remarkable sales in its three other geographic segments: Latin American and Asia-Pacific; Europe, Middle East, and Africa; and Canada. The majority of sales are through wholesale channels, including sporting goods and department stores, but the company also operates its own branded stores in each of its geographic segments. It sources products from around the world and uses contract manufacturers outside the United States, predominantly in Asia to manufacture its various products.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.